,trastuzumab deruxtecan
Daiichi Sankyo,AstraZeneca
['mbc', 'breast']
destiny breast 04. this is what we will see today in the plenary at asco. majority of pts had received more than three lines of therapy in the metastatic setting. this is practice changing. we now have a new standard for our pts with her2 low mbc! #asco2022 
Breast cancer specialist. Shoe lover. Cupcake connoisseuse. Opinions are my own, RTs not an endorsement.